{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:31:41Z","timestamp":1794270701013,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503587"],"award-info":[{"award-number":["82503587"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404059"],"award-info":[{"award-number":["82404059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473184"],"award-info":[{"award-number":["82473184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Sailing Program","award":["24YF2704100"],"award-info":[{"award-number":["24YF2704100"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M781926"],"award-info":[{"award-number":["2025M781926"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2024AZ(EGFR)MS-0048"],"award-info":[{"award-number":["Y-2024AZ(EGFR)MS-0048"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired resistance significantly limits the long-term clinical benefit of osimertinib in EGFR-mutant lung adenocarcinoma (LUAD). However, the early non-genetic adaptations and microenvironmental crosstalk that enable initial tumor survival remain poorly defined. This study aimed to elucidate the epigenetic-immune mechanisms driving osimertinib resistance and to identify novel actionable therapeutic targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated transcriptomic profiling and clinical cohort analyses to identify therapy-induced secreted factors during the evolution of EGFR-TKI resistance. The upstream regulatory mechanisms were characterized using ChIP, Co-IP, and dual-luciferase reporter assays. The dual functional roles of the identified factor, serum amyloid A1 (SAA1), in tumor-intrinsic signaling and macrophage polarization were investigated in vitro. Finally, the therapeutic efficacy of combining SAA1 neutralization with osimertinib was evaluated across patient-derived organoids, xenografts, and immunocompetent spontaneous lung tumor models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified SAA1 as a critical therapy-induced secreted factor that progressively increases during the transition from drug tolerance to established resistance, which negatively correlates with clinical outcomes in patients receiving osimertinib. Mechanistically, osimertinib treatment suppressed the ERK-dependent phosphorylation of the transcriptional repressor GATAD2A at Ser114. This event destabilized the NuRD complex, thereby relieving the epigenetic transcriptional repression of SAA1. Secreted SAA1 promoted therapeutic resistance through dual mechanisms: activating the autocrine TLR4\/NF-\u03baB survival signaling in tumor cells and inducing the paracrine polarization of pro-tumorigenic SPP1\u207a macrophages. Therapeutically, targeted neutralization of SAA1 synergized robustly with osimertinib to reverse immunosuppressive remodeling and induce profound tumor regression in multiple preclinical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings define a novel therapy-induced ERK\/GATAD2A\/SAA1 epigenetic-immune axis that drives acquired resistance to osimertinib. SAA1 acts as a pivotal bridge between tumor-intrinsic survival adaptations and microenvironmental immune suppression, highlighting SAA1 neutralization as a tractable combinatorial strategy to enhance EGFR-TKI efficacy in LUAD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03792-6","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:51:12Z","timestamp":1785207072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ERK\/GATAD2A\/SAA1 axis drives osimertinib resistance via NF-\u03baB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Junkan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"3792_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G, Reck M. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10:71.","journal-title":"Nat Rev Dis Primers"},{"key":"3792_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3792_CR3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023;41:1830\u201340.","journal-title":"J Clin Oncol"},{"key":"3792_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389:137\u201347.","journal-title":"N Engl J Med"},{"key":"3792_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173.","journal-title":"J Hematol Oncol"},{"key":"3792_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","volume":"44","author":"D Miao","year":"2024","unstructured":"Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 2024;44:23\u201346.","journal-title":"Cancer Commun (Lond)"},{"key":"3792_CR7","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Z Zalaquett","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, Planchard D. Acquired resistance mechanisms to osimertinib: The constant battle. Cancer Treat Rev. 2023;116:102557.","journal-title":"Cancer Treat Rev"},{"key":"3792_CR8","doi-asserted-by":"publisher","first-page":"102824","DOI":"10.1016\/j.ctrv.2024.102824","volume":"130","author":"C Corvaja","year":"2024","unstructured":"Corvaja C, Passaro A, Attili I, Aliaga PT, Spitaleri G, Signore ED, de Marinis F. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Cancer Treat Rev. 2024;130:102824.","journal-title":"Cancer Treat Rev"},{"key":"3792_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19:499\u2013514.","journal-title":"Nat Rev Clin Oncol"},{"key":"3792_CR10","doi-asserted-by":"publisher","first-page":"217124","DOI":"10.1016\/j.canlet.2024.217124","volume":"598","author":"R Nakamura","year":"2024","unstructured":"Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer Lett. 2024;598:217124.","journal-title":"Cancer Lett"},{"key":"3792_CR11","doi-asserted-by":"crossref","unstructured":"Remon J, Levy A, Gille R, Martel-Lafay I, Bortolot M, Hendriks LEL, Faivre-Finn C, Leighl N, Reck M, P\u00e9rol M. Unresectable stage III non-small-cell lung cancer: state of the art and challenges. Nat Rev Clin Oncol. 2026;23(1):22\u201339.","DOI":"10.1038\/s41571-025-01080-4"},{"key":"3792_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.jtho.2025.06.007","volume":"20","author":"K Fukuda","year":"2025","unstructured":"Fukuda K, Nanjo S, Takeuchi S, Chakrabarti T, Brown T, Dev Sahadevan SW, Arai S, Sato S, Kotani H, Nishiyama A, Sakaguchi H, Ohtsubo K, Taniguchi H, Blakely CM, Bivona TG, Yano S. Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2025;20:1459\u201374.","journal-title":"J Thorac Oncol"},{"key":"3792_CR13","doi-asserted-by":"publisher","first-page":"218060","DOI":"10.1016\/j.canlet.2025.218060","volume":"634","author":"Z Yin","year":"2025","unstructured":"Yin Z, Zhou Y, Zhu X, Goettl RA, Wang C, Weiss HL, Evers BM, Wang Q. Cancer-associated fibroblast secreted DKK1 promotes the immunosuppressive tumor microenvironment and colorectal cancer resistance to chemotherapy. Cancer Lett. 2025;634:218060.","journal-title":"Cancer Lett"},{"key":"3792_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Zotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405:216\u201332.","journal-title":"Lancet"},{"key":"3792_CR15","doi-asserted-by":"crossref","unstructured":"Lan Y, Yeung TL, Huang H, Wegener AA, Saha S, Toister-Achituv M, Jenkins MH, Chiu LY, Lazorchak A, Tarcic O, Wang H, Qi J, Locke G, Kalimi D, Qin G, Marelli B, Yu H, Gross AW, Derner MG, Soloviev M, Botte M, Sircar A, Ma H, Sood VD, Zhang D, Jiang F, Lo KM. Colocalized targeting of TGF-beta and PD-L1 by bintrafusp alfa elicits distinct antitumor responses. J Immunother Cancer. 2022;10(7):e004122.","DOI":"10.1136\/jitc-2021-004122"},{"key":"3792_CR16","doi-asserted-by":"crossref","unstructured":"Wu Y, Yang F, Luo S, Li X, Gu Z, Fan R, Cao Y, Wang L, Song X. Single-cell RNA sequencing reveals epithelial cells driving brain metastasis in lung adenocarcinoma. Volume 27. iScience; 2024 Feb 16;27(3):109258.","DOI":"10.1016\/j.isci.2024.109258"},{"key":"3792_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1021\/pr101154j","volume":"10","author":"HJ Sung","year":"2011","unstructured":"Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, Lee SY, Kim JW, Cho JY. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2011;10:1383\u201395.","journal-title":"J Proteome Res"},{"key":"3792_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","volume":"25","author":"KN Shah","year":"2019","unstructured":"Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019;25:111\u20138.","journal-title":"Nat Med"},{"key":"3792_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","volume":"41","author":"MB Nilsson","year":"2023","unstructured":"Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023;41:340\u2013e355346.","journal-title":"Cancer Cell"},{"key":"3792_CR20","doi-asserted-by":"crossref","unstructured":"Wu L, Yan J, Bai Y, Chen F, Zou X, Xu J, Huang A, Hou L, Zhong Y, Jing Z, Yu Q, Zhou X, Jiang Z, Wang C, Cheng M, Ji Y, Hou Y, Luo R, Li Q, Wu L, Cheng J, Wang P, Guo D, Huang W, Lei J, Liu S, Yan Y, Chen Y, Liao S, Li Y, Sun H, Yao N, Zhang X, Zhang S, Chen X, Yu Y, Li Y, Liu F, Wang Z, Zhou S, Yang H, Yang S, Xu X, Liu L, Gao Q, Tang Z, Wang X, Wang J, Fan J, Liu S, Yang X, Chen A. J. Zhou, An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression, Cell Res. 2023;33:585\u2013603.","DOI":"10.1038\/s41422-023-00831-1"},{"key":"3792_CR21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, Qin S, Zhang L, Ouyang H, Du P, Jiang L, Zhang B, Yang Y, Wang X, Ren X, Bei JX, Hu X, Bu Z, Ji J, Zhang Z. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184:792\u2013e809723.","journal-title":"Cell"},{"key":"3792_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41580-021-00398-y","volume":"22","author":"NP Blackledge","year":"2021","unstructured":"Blackledge NP, Klose RJ. The molecular principles of gene regulation by Polycomb repressive complexes. Nat Rev Mol Cell Biol. 2021;22:815\u201333.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3792_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41580-023-00624-9","volume":"25","author":"J Brito Querido","year":"2024","unstructured":"Brito Querido J, Diaz-Lopez I, Ramakrishnan V. The molecular basis of translation initiation and its regulation in eukaryotes. Nat Rev Mol Cell Biol. 2024;25:168\u201386.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3792_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41573-024-01080-6","volume":"24","author":"MM Zhou","year":"2025","unstructured":"Zhou MM, Cole PA. Targeting lysine acetylation readers and writers. Nat Rev Drug Discov. 2025;24:112\u201333.","journal-title":"Nat Rev Drug Discov"},{"key":"3792_CR25","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ccell.2024.09.006","volume":"42","author":"H Li","year":"2024","unstructured":"Li H, Sun L, Gao P, Hu H. Lactylation in cancer: Current understanding and challenges. Cancer Cell. 2024;42:1803\u20137.","journal-title":"Cancer Cell"},{"key":"3792_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","volume":"9","author":"M He","year":"2024","unstructured":"He M, Zhou X, Wang X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduct Target Ther. 2024;9:194.","journal-title":"Signal Transduct Target Ther"},{"key":"3792_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12943-025-02397-5","volume":"24","author":"H Jia","year":"2025","unstructured":"Jia H, Jiang L, Shen X, Ye H, Li X, Zhang L, Hu Y, Song D, Jia H, Wang Z. Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies. Mol Cancer. 2025;24:193.","journal-title":"Mol Cancer"},{"key":"3792_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","volume":"84","author":"E Kovacs","year":"2015","unstructured":"Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 2015;84:739\u201364.","journal-title":"Annu Rev Biochem"},{"key":"3792_CR29","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1093\/nar\/gkg584","volume":"31","author":"JC Obenauer","year":"2003","unstructured":"Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 2003;31:3635\u201341.","journal-title":"Nucleic Acids Res"},{"key":"3792_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cmet.2016.10.004","volume":"25","author":"MS Robles","year":"2017","unstructured":"Robles MS, Humphrey SJ, Mann M. Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. Cell Metab. 2017;25:118\u201327.","journal-title":"Cell Metab"},{"key":"3792_CR31","doi-asserted-by":"publisher","first-page":"e2315242121","DOI":"10.1073\/pnas.2315242121","volume":"121","author":"M Boren\u00e4s","year":"2024","unstructured":"Boren\u00e4s M, Umapathy G, Lind DE, Lai WY, Guan J, Johansson J, Jennische E, Schmidt A, Kurhe Y, Gabre JL, Aniszewska A, Str\u00f6mberg A, Bemark M, Hall MN, Eynden JVD, Hallberg B, Palmer RH. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. Proc Natl Acad Sci U S A. 2024;121:e2315242121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3792_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41556-025-01657-2","volume":"27","author":"H Wei","year":"2025","unstructured":"Wei H, Zheng H, Wang S, Yang Y, Zhao R, Gu A, Hu R, Lan F, Wen W. Targeting redox-sensitive MBD2-NuRD condensate in cancer cells. Nat Cell Biol. 2025;27:801\u201316.","journal-title":"Nat Cell Biol"},{"key":"3792_CR33","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41590-020-0698-1","volume":"21","author":"U Smole","year":"2020","unstructured":"Smole U, Gour N, Phelan J, Hofer G, K\u00f6hler C, Kratzer B, Tauber PA, Xiao X, Yao N, Dvorak J, Caraballo L, Puerta L, Rosskopf S, Chakir J, Malle E, Lane AP, Pickl WF, Lajoie S. Wills-Karp, Serum amyloid A is a soluble pattern recognition receptor that drives type 2 immunity. Nat Immunol. 2020;21:756\u201365.","journal-title":"Nat Immunol"},{"key":"3792_CR34","doi-asserted-by":"publisher","first-page":"217962","DOI":"10.1016\/j.canlet.2025.217962","volume":"632","author":"G Ma","year":"2025","unstructured":"Ma G, Wang D, Deng Y, Huang W, Zhai Y, Sun SY. Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib. Cancer Lett. 2025;632:217962.","journal-title":"Cancer Lett"},{"key":"3792_CR35","first-page":"101284","volume":"31","author":"MS Haines","year":"2022","unstructured":"Haines MS, Ramirez E, Moore KBE, Fortin JS. Revisiting misfolding propensity of serum amyloid A1: Special focus on the signal peptide region. Biochem Biophys Rep. 2022;31:101284.","journal-title":"Biochem Biophys Rep"},{"key":"3792_CR36","doi-asserted-by":"publisher","first-page":"101042","DOI":"10.1016\/j.drup.2023.101042","volume":"73","author":"Y Li","year":"2024","unstructured":"Li Y, Zhao B, Peng J, Tang H, Wang S, Peng S, Ye F, Wang J, Ouyang K, Li J, Cai M, Chen Y. Inhibition of NF-kappaB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resist Updat. 2024;73:101042.","journal-title":"Drug Resist Updat"},{"key":"3792_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14728222.2023.2225767","volume":"27","author":"D Wu","year":"2023","unstructured":"Wu D, Tian S, Zhu W. Modulating multidrug resistance to drug-based antitumor therapies through NF-kappaB signaling pathway: mechanisms and perspectives. Expert Opin Ther Targets. 2023;27:503\u201315.","journal-title":"Expert Opin Ther Targets"},{"key":"3792_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","volume":"8","author":"K Jacobsen","year":"2017","unstructured":"Jacobsen K, Bertran-Alamillo J, Molina MA, Teixido C, Karachaliou N, Pedersen MH, Castellvi J, Garzon M, Codony-Servat C, Codony-Servat J, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017;8:410.","journal-title":"Nat Commun"},{"key":"3792_CR39","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-16-1955","volume":"23","author":"DS Hsu","year":"2017","unstructured":"Hsu DS, Hwang WL, Yuh CH, Chu CH, Ho YH, Chen PB, Lin HS, Lin HK, Wu SP, Lin CY, Hsu WH, Lan HY, Wang HJ, Tai SK, Hung MC, Yang MH. Lymphotoxin-beta Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer. Clin Cancer Res. 2017;23:4388\u2013401.","journal-title":"Clin Cancer Res"},{"key":"3792_CR40","doi-asserted-by":"publisher","first-page":"102513","DOI":"10.1016\/j.xcrm.2025.102513","volume":"6","author":"Y Chen","year":"2025","unstructured":"Chen Y, Dou R, Hong MJ, Xu H, Vykoukal J, Le\u00f3n-Letelier RA, Cai Y, Park S, Irajizad E, Hsiao FC, Dennison JB, Ostrin EJ, Fahrmann JF, Katayama H, Hanash SM. Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy. Cell Rep Med. 2025;6:102513.","journal-title":"Cell Rep Med"},{"key":"3792_CR41","doi-asserted-by":"crossref","unstructured":"Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O\u2019Brien SA, He Y, Wang L, Zhang Q, Kim A, Gao R, Orf J, Wang T, Sawant D, Kang J, Bhatt D, Lu D, Li CM, Rapaport AS, Perez K, Ye Y, Wang S, Hu X, Ren X, Ouyang W, Shen Z, Egen JG, Zhang Z, Yu X. Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer, Cell. 2020;181:442\u2013459.e429.","DOI":"10.1016\/j.cell.2020.03.048"},{"key":"3792_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13046-024-03255-w","volume":"43","author":"C Liu","year":"2024","unstructured":"Liu C, Wu K, Li C, Zhang Z, Zhai P, Guo H, Zhang J. SPP1\u2009+\u2009macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-\u03b1 and IL-1\u03b2. J Exp Clin Cancer Res. 2024;43:332.","journal-title":"J Exp Clin Cancer Res"},{"key":"3792_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1134\/S0006297912040037","volume":"77","author":"SA Moshkovskii","year":"2012","unstructured":"Moshkovskii SA. Why do cancer cells produce serum amyloid A acute-phase protein? Biochem (Mosc). 2012;77:339\u201341.","journal-title":"Biochem (Mosc)"},{"key":"3792_CR44","doi-asserted-by":"crossref","unstructured":"Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH, Lin WY, Yeung ST, Silva HM, Li D, Hine A, Loke P, Hudesman D, Martin JC, Kenigsberg E, Merad M, Khanna KM, Littman DR. Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease, Cell. 2020;180:79\u201391.e16.","DOI":"10.1016\/j.cell.2019.11.026"},{"key":"3792_CR45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/carcin\/bgaa131","volume":"42","author":"Y Yasukawa","year":"2021","unstructured":"Yasukawa Y, Hattori N, Iida N, Takeshima H, Maeda M, Kiyono T, Sekine S, Seto Y, Ushijima T. SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation. Carcinogenesis. 2021;42:180\u20139.","journal-title":"Carcinogenesis"},{"key":"3792_CR46","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1038\/s41467-022-32143-0","volume":"13","author":"A Avni","year":"2022","unstructured":"Avni A, Joshi A, Walimbe A, Pattanashetty SG, Mukhopadhyay S. Single-droplet surface-enhanced Raman scattering decodes the molecular determinants of liquid-liquid phase separation. Nat Commun. 2022;13:4378.","journal-title":"Nat Commun"},{"key":"3792_CR47","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1039\/D3CS01065A","volume":"53","author":"S Mukherjee","year":"2024","unstructured":"Mukherjee S, Poudyal M, Dave K, Kadu P, Maji SK. Protein misfolding and amyloid nucleation through liquid-liquid phase separation. Chem Soc Rev. 2024;53:4976\u20135013.","journal-title":"Chem Soc Rev"},{"key":"3792_CR48","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1038\/s41467-023-39551-w","volume":"14","author":"N Schmolka","year":"2023","unstructured":"Schmolka N, Karemaker ID, Cardoso da Silva R, Recchia DC, Spegg V, Bhaskaran J, Teske M, de Wagenaar NP, Altmeyer M, Baubec T. Dissecting the roles of MBD2 isoforms and domains in regulating NuRD complex function during cellular differentiation. Nat Commun. 2023;14:3848.","journal-title":"Nat Commun"},{"key":"3792_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/svn-2024-003525","volume":"10","author":"H Zhu","year":"2025","unstructured":"Zhu H, Wang N, Chang Y, Zhang Y, Jiang S, Ren X, Yuan M, Chang H, Jin WN. Extracellular vesicles bearing serum amyloid A1 exacerbate neuroinflammation after intracerebral haemorrhage. Stroke Vasc Neurol. 2025;10:347\u201358.","journal-title":"Stroke Vasc Neurol"},{"key":"3792_CR50","doi-asserted-by":"publisher","first-page":"113771","DOI":"10.1016\/j.celrep.2024.113771","volume":"43","author":"J Liang","year":"2024","unstructured":"Liang J, Bi G, Sui Q, Zhao G, Zhang H, Bian Y, Chen Z, Huang Y, Xi J, Shi Y, Wang Q, Zhan C. Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. Cell Rep. 2024;43:113771.","journal-title":"Cell Rep"},{"key":"3792_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12931-025-03278-7","volume":"26","author":"S Ren","year":"2025","unstructured":"Ren S, Zhu J, Shan G, Liang J, Bian Y, Lin H, Shi H, Pan B, Zhao G, Yang H, Huang X, Zhan C, Ge D, Bi G. Transcription factor ZNF266 suppresses cancer progression by modulating CA9-mediated intracellular pH alteration in lung adenocarcinoma. Respir Res. 2025;26:191.","journal-title":"Respir Res"},{"key":"3792_CR52","doi-asserted-by":"publisher","first-page":"9923","DOI":"10.1038\/s41467-025-65441-4","volume":"16","author":"Y Bian","year":"2025","unstructured":"Bian Y, Shan G, Bi G, Xu Z, Liang J, Yan Y, Guo W, Sui Q, Yi Y, Shi H, Lu T, Zhang H, Wang Q, Fan H, Jiang W, Zhan C. Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status. Nat Commun. 2025;16:9923.","journal-title":"Nat Commun"},{"key":"3792_CR53","doi-asserted-by":"publisher","first-page":"218069","DOI":"10.1016\/j.canlet.2025.218069","volume":"634","author":"X Huang","year":"2025","unstructured":"Huang X, Liang J, Yi Y, Zhu J, Lin H, Ren S, Cheng T, Bi G, Shan G, Zeng D, Xu F, Ge D, Zhan C. Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma. Cancer Lett. 2025;634:218069.","journal-title":"Cancer Lett"},{"key":"3792_CR54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/7651_2020_307","volume":"2346","author":"RR Chaparian","year":"2021","unstructured":"Chaparian RR, van Kessel JC. Promoter Pull-Down Assay: A Biochemical Screen for DNA-Binding Proteins. Methods Mol Biol. 2021;2346:165\u201372.","journal-title":"Methods Mol Biol"},{"key":"3792_CR55","doi-asserted-by":"publisher","first-page":"101057","DOI":"10.1016\/j.drup.2024.101057","volume":"73","author":"J Liang","year":"2024","unstructured":"Liang J, Bi G, Huang Y, Zhao G, Sui Q, Zhang H, Bian Y, Yin J, Wang Q, Chen Z, Zhan C. MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma. Drug Resist Updat. 2024;73:101057.","journal-title":"Drug Resist Updat"},{"key":"3792_CR56","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","volume":"51","author":"UniProt","year":"2023","unstructured":"UniProt. the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023;51:D523\u201331.","journal-title":"Nucleic Acids Res"},{"key":"3792_CR57","doi-asserted-by":"crossref","unstructured":"Liang J, Bi G, Huang X, Xu Z, Huang Y, Bian Y, Shan G, Guo W, Yan Y, Sui Q, Yang X, Chen Z, Lu T, Zhang H, Wang Q, Jiang W, Zhan C. CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer. Cancer Commun (Lond). 2025;45(11):1547\u201378.","DOI":"10.1002\/cac2.70068"},{"key":"3792_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41421-025-00829-6","volume":"11","author":"G Shan","year":"2025","unstructured":"Shan G, Bian Y, Sui Q, Liang J, Ren S, Pan B, Shi H, Zheng Z, Zeng D, Zhu J, Chen Z, Bi G, Fan H, Zhan C. Ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing ACSL4 degradation in lung adenocarcinoma. Cell Discov. 2025;11:81.","journal-title":"Cell Discov"},{"key":"3792_CR59","doi-asserted-by":"publisher","first-page":"D912","DOI":"10.1093\/nar\/gkr1012","volume":"40","author":"KR Rosenbloom","year":"2012","unstructured":"Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ, Cline MS, Karolchik D, Barber GP, Clawson H, Diekhans M, Fujita PA, Goldman M, Gravell RC, Harte RA, Hinrichs AS, Kirkup VM, Kuhn RM, Learned K, Maddren M, Meyer LR, Pohl A, Rhead B, Wong MC, Zweig AS, Haussler D, Kent WJ. ENCODE whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res. 2012;40:D912\u2013917.","journal-title":"Nucleic Acids Res"},{"key":"3792_CR60","doi-asserted-by":"publisher","first-page":"W39","DOI":"10.1093\/nar\/gkv416","volume":"43","author":"TL Bailey","year":"2015","unstructured":"Bailey TL, Johnson J, Grant CE, Noble WS. The MEME Suite. Nucleic Acids Res. 2015;43:W39\u201349.","journal-title":"Nucleic Acids Res"},{"key":"3792_CR61","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. Smyth, limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"3792_CR62","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284\u20137.","journal-title":"Omics"},{"key":"3792_CR63","doi-asserted-by":"publisher","first-page":"D104","DOI":"10.1093\/nar\/gkaa1057","volume":"49","author":"S Kolmykov","year":"2021","unstructured":"Kolmykov S, Yevshin I, Kulyashov M, Sharipov R, Kondrakhin Y, Makeev VJ, Kulakovskiy IV, Kel A, Kolpakov F. GTRD: an integrated view of transcription regulation. Nucleic Acids Res. 2021;49:D104\u201311.","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03792-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:37:32Z","timestamp":1792730252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03792-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3792"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03792-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Zhongshan Hospital, Fudan University granted approval for our research (Approval No. B2023-258), ensuring adherence to the Helsinki Declaration and the Guide for the Ethical Review of Animal Welfare (GB\/T 35892\u2009\u2212\u20092018).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors reviewed and approved the final manuscript for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"221"}}